Trial record 1 of 1 for:
nct 04460235
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma (HEMATOVAC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04460235 |
|
Recruitment Status :
Recruiting
First Posted : July 7, 2020
Last Update Posted : February 12, 2024
|
Sponsor:
Poitiers University Hospital
Information provided by (Responsible Party):
Poitiers University Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The French Public Health Council recommended pneumococcal vaccination combined strategy for all immunocompromised patients in 2012. This strategy consisted in conjugated 13-valent pneumococcal injection followed 2 months later by polysaccharide 23-valent vaccine injection. General practitioners are usually in charge of this vaccination. Conjugated pneumococcal vaccine enhances the immunogenicity of the polysaccharide vaccine. Acute leukemia and lymphoma are treated with multiple courses of chemotherapy, impairing the immune system and potentially the response to vaccination. These patients are more at risk for developing pneumococcal invasive diseases than the general population. However, efficacy of pneumococcal vaccination is poorly documented in this setting. We assume that 70% of the patients are non-responders to vaccination, according to their anti-pneumococcal immunoglobulin G titers and the opsonophagocytic activity. To assess the immunogenicity of the pneumococcal vaccination combined strategy in adult population of acute leukemia and lymphoma, the investigator will measure anti-pneumococcal serotype-specific immunoglobulin G titers and opsonophagocytic activity at different time-points after completion of the combined vaccine strategy. The primary objective is to assess the immunogenicity of pneumococcal vaccination combined strategy at 3 months after the 13-valent pneumococcal injection (corresponding to 1 month after the end of the combined strategy) using immunoglobulin G titers and opsonophagocytic activity. At different time points (day 0, 1 month after the 13-valent pneumococcal injection, the day of the injection of the polysaccharide 23-valent vaccine, one month after the injection of the polysaccharide 23-valent vaccine, 3-6 months after the polysaccharide 23-valent vaccine,9-12 months after the polysaccharide 23-valent vaccine), the immunological response to vaccination will be monitored using specific-serotype immunoglobulin G titers, opsonophagocytic activity, and total anti-pneumococcal Immunoglobulin. The investigator will determine predictive factors of non-response to vaccination by comparing demographic data, biological data and treatment received by both acute myeloblastic leukemia and lymphoma patients. The tolerance and safety of the vaccination strategy will also be assessed in this specific hematological population.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Vaccine Streptococcus Pneumoniae Acute Myeloid Leukemia Lymphoma, Non-Hodgkin | Drug: Prevenar13 Pneumo-23 | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 160 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte |
| Actual Study Start Date : | September 9, 2021 |
| Estimated Primary Completion Date : | June 2026 |
| Estimated Study Completion Date : | June 2026 |
Resource links provided by the National Library of Medicine
Drug Information
available for:
Heptavalent pneumococcal conjugate vaccine
| Arm | Intervention/treatment |
|---|---|
|
Vaccination
All patients will be vaccinated according to national guidelines
|
Drug: Prevenar13 Pneumo-23
Vaccination according national guidelines |
Primary Outcome Measures :
- Proportion of patients having a good response to combined strategy [ Time Frame: 39 months ]Proportion of patients having a good response to combined strategy at 4 weeks after the end of the combined strategy. A good response to vaccination is defined by 4/7 tested serotypes responding to these 4 criteria: a serotype-specific immunoglobulin G titer ≥ 1μg/L (WHO threshold), a two-fold increase of this immunoglobulin G titer compare to baseline before vaccination, a serotype-specific opsonophagocytic activity ≥1/8, and a four-fold increase of functional antibodies compare to baseline.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient ≥ 18 year-old.
- AND medical follow-up in hematology unit
- AND had received a first course of chemotherapy except demethylating for acute myeloblastic leukemia without ProMyelogenousLeukemia-RetinoicAcidReceptor alpha and no planned allogeneic hematopoietic stem cell transplantation (anti-IDH treatment authorized) or for diffuse large B cell lymphoma or for follicular lymphoma
- Life expectancy > 6 months
- Having signed the consent form
- Having an health insurance
Exclusion Criteria:
- Receiving monoclonal antibodies or biotherapies altering the immune response, other than anti-Cluster of differentiation number 20 antibodies in the chemotherapy protocol.
- Uncontrolled bacterial, viral or fungal infection less than 7 days
- Previous vaccination with 13-valent pneumococcal vaccine or polysaccharide 23-valent vaccine (unless 13-valent pneumococcal vaccine was administered in childhood. The last injection must be performed at least five years ago)
- Preexisting condition that altered the immune response: splenectomy, HIV, primary or secondary immune deficiency, nephrotic syndrome, sickle cell anemia, autoimmune disorder, solid organ transplantation, immunosuppressive drugs or biotherapy not included in the chemotherapy
- Patient who already received chemotherapy for malignancy in the previous 2 years before the inclusion
- Allogeneic hematopoietic stem cell transplantation planned in the following 3 months after the first chemotherapy course
- Major blood clotting disorders preventing intramuscular injection
- Medical history of anaphylactic reaction to vaccination
- Known allergy to one of the vaccine components
- Involvement to another vaccine biomedical research
- Protected person
- Pregnant women or women of childbearing age without appropriate contraceptive measures
- Perfusion of polyvalent immunoglobulins during follow-up
- Participants with hypersensitivity to aluminum phosphate, phenol or CRM197 protein, protein derived from Corynebacterium diphtheria.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04460235
Contacts
| Contact: Mathieu Puyade, MD, PhD | 0033 5 49 44 32 76 | mathieu.puyade@chu-poitiers.fr | |
| Contact: Fanny Abriat | 0033 5 49 44 37 96 | fanny.abriat@chu-poitiers.fr |
Locations
| France | |
| Chu Angers | Recruiting |
| Angers, France | |
| Contact: Mathilde HUNAULT, Pr | |
| CHU Bordeaux | Recruiting |
| Bordeaux, France | |
| Contact: François-Xavier GROS, Dr | |
| CHU Limoges | Recruiting |
| Limoges, France | |
| Contact: Arnaud JACCARD, Pr | |
| Chu Nantes | Recruiting |
| Nantes, France | |
| Contact: Pierre PETERLIN, Dr | |
| CHU Poitiers | Recruiting |
| Poitiers, France | |
| Contact: Maria Pilar GALLEGO HERNANZ, Dr | |
| Ch Perigueux | Recruiting |
| Périgueux, France | |
| Contact: Claire CALMETTES, Dr | |
| CHU Tours | Recruiting |
| Tours, France | |
| Contact: Antoine MACHET, Dr | |
Sponsors and Collaborators
Poitiers University Hospital
| Responsible Party: | Poitiers University Hospital |
| ClinicalTrials.gov Identifier: | NCT04460235 |
| Other Study ID Numbers: |
HEMATOVAC |
| First Posted: | July 7, 2020 Key Record Dates |
| Last Update Posted: | February 12, 2024 |
| Last Verified: | January 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
|
Pneumonia, Pneumococcal Lymphoma Leukemia Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Hematologic Diseases Pneumonia Respiratory Tract Infections |
Infections Lung Diseases Respiratory Tract Diseases Pneumococcal Infections Streptococcal Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Pneumonia, Bacterial Heptavalent Pneumococcal Conjugate Vaccine Immunologic Factors Physiological Effects of Drugs |